REFERENCES


16. S. Yoshioka, Stella V.J., Stability of Drugs and Dosage forms, Chapter 2-Chemical stability of drug substances, pg.no. 4.


39. Lindenberg M, Kopp S, Dressman JB.; Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines
according to the biopharmaceutics classification system; Eur J Pharm Biopharm, 2004; 58: 265-278.


104. Xiaomei Wang, Na Chi, Xing Tang; Preparation of estradiol chitosan nanoparticles for improving nasal absorption and brain targeting; European Journal of Pharmaceutics and Biopharmaceutics, 2008;70:735–740.


112. BASF Corporation, 3000 Continental Drive-North Mount Olive, New Jersey.


132. Guidance for industry, estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers US department of health and human services, FDA centre for drug evaluation and research (CDER), July 2005, Pharmacology and Toxicology.


137. International Conference on the Harmonization of Technical Requirements for the Registration of Pharmaceuticals for Human Use (ICH) Q2B; Validation of Analytical Procedures: Methodology, November 6, 1996; London, UK.


139. Yoshioka S., Stella V. J., Stability of Drugs and Dosage forms, Chapter 2-Chemical stability of drug substances, pg.no. 4.


